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Histone methylation and the enzymes that mediate it are important regulators of chromatin structure and
gene transcription. In particular, the histone H3 lysine 36 (K36) methyltransferase Set2 has recently been
shown to associate with the phosphorylated C-terminal domain (CTD) of RNA polymerase II (RNAPII),
implying that this enzyme has an important role in the transcription elongation process. Here we show that a
novel domain in the C terminus of Set2 is responsible for interaction between Set2 and RNAPII. This domain,
termed the Set2 Rpb1 interacting (SRI) domain, is encompassed by amino acid residues 619 to 718 in Set2 and
is found to occur in a number of putative Set2 homologs from Schizosaccharomyces pombe to humans. Unex-
pectedly, BIACORE analysis reveals that the SRI domain binds specifically, and with high affinity, to CTD
repeats that are doubly modified (serine 2 and serine 5 phosphorylated), indicating that Set2 association across
the body of genes requires a specific pattern of phosphorylated RNAPII. Deletion of the SRI domain not only
abolishes Set2-RNAPII interaction but also abolishes K36 methylation in vivo, indicating that this interaction
is required for establishing K36 methylation on chromatin. Using 6-azauracil (6AU) as an indicator of
transcription elongation defects, we found that deletion of the SRI domain conferred a strong resistance to this
compound, which was identical to that observed with set2 deletion mutants. Furthermore, yeast strains carrying
set2 alleles that are catalytically inactive or yeast strains bearing point mutations at K36 were also found to be
resistant to 6AU. These data suggest that it is the methylation by Set2 that affects transcription elongation. In
agreement with this, we have determined that deletion of SET2, its SRI domain, or amino acid substitutions
at K36 result in an alteration of RNAPII occupancy levels over transcribing genes. Taken together, these data
indicate K36 methylation, established by the SRI domain-mediated association of Set2 with RNAPII, plays an
important role in the transcription elongation process.
Successful synthesis of mRNA by RNA polymerase II
(RNAPII) requires tight regulation of the initiation, elonga-
tion, and termination processes of transcription. The process
of transcription elongation is affected in part by the binding of
regulatory factors to the phosphorylated C-terminal domain
(CTD) of the RNAPII subunit Rpb1. Recent studies have
highlighted an important role for histone methylation in the
process of transcription elongation. In particular, studies have
shown that the Set1 and Set2 methyltransferases, which cata-
lyze methylation of histone H3 lysines 4 (K4) and 36 (K36),
respectively, are associated with RNAPII at different stages of
the transcription elongation cycle. While Set1 associates with
RNAPII via the Paf1 transcription elongation complex in a
manner that is dependent on the serine 5 (Ser5)-phosphory-
lated CTD, Set2 is recruited to RNAPII in a manner that is
dependent on the CTD and the Ctk1 kinase (CTDK-I) that
effects serine 2 CTD phosphorylation (10, 11, 18, 19, 21, 29,
42). Importantly, while studies show that Set1 preferentially
associates with the 5 end of genes, Set2 is found throughout
the coding regions of genes (19, 29, 33, 42). These observations
imply that K4 and K36 methylation have differing roles in the
transcription elongation process.
Several lines of evidence indicate that Set2 is a phospho-
CTD binding protein (10, 11, 19, 21, 22, 29, 42). For example,
truncations of the RNAPII CTD severely reduce global K36
methylation levels in vivo (21, 42). In addition, deletion of
CTDK-I results in a total abolition of K36 methylation (19, 42).
These data have led to the model that Set2 preferentially binds
to RNAPII that is phosphorylated at the Ser2 position of the
CTD, which is supported by findings that Set2 binds to Ser2-
phosphorylated CTD repeats in vitro (21, 22). Thus, a function
for the CTDK-I-generated phospho-CTD in either the recruit-
ment of Set2 and/or the control of K36 methylation activity has
been proposed (36, 37).
While the association of Set2 with RNAPII is well estab-
lished, the precise region(s) in Set2 required for this interac-
tion, as well as the functional significance of this interaction on
K36 methylation and transcription elongation, is poorly de-
fined. In this report, we uncover a region in Set2 that mediates
RNAPII interaction. We show that deletion of this Set2-Rpb1
interaction (SRI) domain abolishes K36 methylation on chro-
matin in vivo and leads to a transcription elongation defect, as
assayed with 6-azauracil (6AU). In support of a direct role for
Set2 methylation in the transcription elongation process, we
find that set2 mutants or H3 K36 point mutations that prevent
K36 methylation result in 6AU phenotypes similar to those of
a complete SET2 deletion, which we in turn correlate with
altered distribution of RNAPII along genes. These results de-
fine a novel domain in Set2 responsible for functional interac-
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tion with RNAPII and strongly suggest that the K36 methyl-
ation mediated by Set2 influences transcription elongation.
MATERIALS AND METHODS
Yeast strains. The p3Flag-KanMX plasmid was used as a PCR template for
genomic tagging of Saccharomyces cerevisiae Set2 (9). This provided for the
generation of either full-length Set2 (Set2-3Flag) or a form with the SRI domain
deleted [Set2(1-618)-3Flag] by homologous recombination. Primers used to gen-
erate Set2-3Flag in the BY4742 background were constructed previously (42).
The primers for Set2(1-618)-3Flag were 5-CAAAAGGAAGAGTCCAAAAAA
CTAGTGGAAGCAAAAGAGGCTAAGCGGTTGAAAAGGGAACAAAA
GCTGGAG-3 (forward) and 5-AAAGAATTTATTCCAGTTGTGCTCTAG
TCTTTGGGACTGGGAGACCGTTTTTCTTTACTATAGGGCGAATTGG
GT-3 (reverse). Bases which anneal to the p3Flag-KanMX plasmid are
underlined, while the remaining sequence corresponds to the SET2 locus inser-
tion position. The set2 and wild-type (WT) strains of the BY4742 background
were obtained from Research Genetics, while the YCB652 strain, carrying an
integrated URA3 gene, was obtained from Jeff Smith, University of Virginia
School of Medicine (38). The SET2 gene was deleted in the W303 and YCB652
backgrounds by using a PCR product amplified from genomic DNA obtained
from the BY4742 set2 strain, in which the SET2 gene had already been replaced
by the KanMX gene (Research Genetics).
The H3/H4 shuffle strain WZY42 (in the S288C background) was used in 6AU
analyses of H3 point mutants, and replacement of WT H3 with H3 mutants was
accomplished as described previously (5, 44). Plasmids coding for the H3 S10A
and K4R mutants have been described previously (5, 13). All other H3 point
mutations were prepared by standard PCR-based site-directed mutagenesis us-
ing materials and methods previously described (5, 44).
Yeast WCE and nuclei preparation. Yeast whole-cell extracts (WCEs) were
prepared as described previously, but differed in the extraction buffer (42). The
extraction buffer used consisted of 50 mM Tris-HCl at pH 8.0, 300 mM NaCl, 1
mM Mg(C2H3O2)2, 1 mM imidazole, 0.1% NP-40, 0.5 mM EDTA, and 10%
glycerol. In addition, this buffer contained 0.5% phosphatase inhibitor cocktail I
(Sigma), phenylmethylsulfonyl fluoride (2 mM), and leupeptin-pepstatin-aproti-
nin mix (each at 2 g/ml). Nuclear extracts were prepared as previously described
from strains grown in 200 ml of yeast extract-peptone-dextrose medium to an
optical density at 600 nm (OD600) of 1.5 (7).
Electrophoresis and immunoblotting. Western blotting and sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) analyses were per-
formed according to procedures and reagents obtained from Amersham Life
Sciences. The ECL Plus Western blotting detection kit (Amersham Pharmacia
Biotech) was used for specific antibody detection. The rabbit anti-Me2(K36)
antibody was obtained from Upstate Biotechnology Inc. and used at a dilution of
1:3,000. The antibody targeted against the C terminus of H3 was obtained from
Abcam Inc. (AB1791) and used at a dilution of 1:5,000. The anti-phospho-CTD
antibodies H5 and H14 were obtained from Covance, Inc.
Generation of SET2 expression constructs. The Set2 constructs containing a
C-terminal Flag epitope [Set2(1-618), Set2(262-475), Set2(445-538), Set2(528-638),
Set2(619-733), Set2(634-733), Set2(619-718), and Set2(619-703)] were generated by PCR
amplification using Vent DNA polymerase (New England BioLabs) and the
Set2-Flag PN823 expression construct as the template. Full-length Set2,
Set2(1-261), and Set2R195G constructs were prepared previously (39, 42). The PCR
products were cloned into the PN823 yeast expression plasmid and sequenced for
accuracy. Primer sequences are available upon request. For in vitro phospho-
CTD binding experiments, the Set2(1-618) and Set2(619-733) constructs were sub-
cloned into the pMAL-c2G vector (New England BioLabs), and proteins were
purified according to the manufacturer’s protocol.
Immunoprecipitations. Coimmunoprecipitation (co-IP) experiments involving
the various mutant Set2-Flag constructs or Set2-3Flag strains were performed
essentially as previously described (42). In brief, a set2 strain (in the BY4742
background) was transformed with the indicated series of Set2 expression con-
structs and grown to an OD600 of 1.0 in synthetic complete medium lacking
uracil, and WCEs were prepared using the extraction buffer described above.
Co-IPs were performed in a final volume of 0.9 ml, equalized with extraction
buffer containing 1.5 mg of WCE protein (or 2.0 mg for genomically tagged
strains). The extracts were incubated with 12.5 l of preequilibrated anti-Flag
affinity beads (M2; Sigma) for 2 h at 4°C, after which extracts were washed three
times for 2 min in extraction buffer. The beads were eluted in SDS-PAGE
loading buffer with incubation at 100°C for 5 min, and bead-bound proteins were
analyzed by immunoblotting with antibodies targeted against the phospho-CTD.
ChIP assays. The chromatin immunoprecipitation (ChIP) assay using the H3
K36 dimethyl antibody was performed as described previously (42). Primers were
used to amplify regions of SCC2 in the following ranges relative to the ATG start
site: 277 to 27, 2 to 238, 984 to 1222, 3044 to 3276, 3981 to 4222, and 4489 to
4679. Intergenic chromosome V primers were used as a reference and loading
control, as previously reported (17). The previously characterized general
RNAPII-CTD antibody (not specific to any CTD modification state) was used in
ChIP assays for RNAPII detection (34).
Set2-3Flag and Set2(1-618)-3Flag purification. Set2-3Flag and Set2(1-618)-3Flag
proteins were purified as previously described (42). A Coomassie-stained gel was
used to visualize the associated proteins, and mass spectrometry analysis con-
firmed the presence or absence of Rpb1 and Rpb2 from excised gel slices.
In vitro HMT assays. The Escherichia coli strain BL21 was transformed with
pMAL vectors expressing the constructs maltose binding protein (MBP)-Set2
and MBP-Set2(1-618), which also contained the C-terminally tagged Flag epitope.
Protein expression was induced in 100 M isopropyl--D-thiogalactopyranoside
for 3 h at 30°C, cells were lysed by sonication, and 20-l histone methyltrans-
ferase (HMT) reaction mixtures were prepared as described previously (39). In
brief, lysate volumes were used that resulted in equal amounts of each MBP-Set2
fusion per reaction mixture, as analyzed by Western blotting with the Flag
antibody. HMT reaction mixtures contained 1 Ci of S-adenosyl-L-[methyl-
3H]methionine (Amersham Biosciences), with or without 6 g of chicken nu-
cleosomes. Reaction mixtures were incubated at 30°C for 20 min and spotted on
Whatman P-81 for liquid scintillation counting or analyzed by SDS-PAGE fol-
lowed by fluorography.
Far Western analysis of Set2 fragments using phospho-CTD probes. Far
Western analysis using a phospho-CTD probe (generated by CTDK-I) was per-
formed essentially as described previously (26, 27). In brief, picomole quantities
of recombinant MBP-Set2(1-618) and MBP-Set2(619-733) were resolved on a 4-to-
15% Tris-HCl criterion gel (Bio-Rad) and transferred to nitrocellulose (Hybond
C Extra; Amersham Pharmacia Biotech). The nitrocellulose was stained with
Ponceau S to visually ensure protein transfer from the gel. The membrane was
blocked at 4°C for 24 h and probed with 2.5 g of glutathione S-transferase
(GST)–[32P]CTD in blocking buffer for 3.5 h at 4°C. The membrane was washed,
air dried, and exposed to film. Reverse far Western analysis was performed
according to published methods by resolving recombinant unphosphorylated or
phosphorylated GST-CTD fusions on a 4-to-15% Tris-HCl gel (31). The gel was
transferred to a nitrocellulose membrane and probed with MBP-Set2 or MBP-
Set2(619-733), followed by detection using an antibody against MBP.
Determination of SRI-CTD specificity by using BIACORE. The BIACORE
sensor chip carrying three-repeat CTD peptides phosphorylated at either Ser2
(2-phospho), Ser5 (5-phospho), or both (2  5-phospho) or a control Ser-
phosphorylated peptide that mimics the charge state of the 2  5-phospho
peptide (6PC scrambled control) was generated as previously recorded (16, 31).
Purified MBP-Set2(619-733) was interacted with the peptides, and association and
dissociation were monitored. The response curves were normalized to that for
the 6PC control peptide.
RT-PCR. Reverse transcription (RT)-PCR analysis was performed as previ-
ously described (42, 43). Primer sequences are available upon request.
6AU growth assays. Yeast strains used in this assay, except for YCB652, were
transformed with the URA3 CEN plasmid pRS316 and grown in synthetic
defined medium lacking uracil (SD-Ura). Overnight cultures were diluted 1:20
and grown to an OD600 of 1.0, and 10-fold serial dilutions were plated on SD-Ura
medium with or without 6AU (Aldrich) or mycophenolic acid (Sigma), each at
100 g/ml. Plates were photographed after 30°C incubation for 2 to 3 days.
Liquid cultures used for RT-PCR analysis were grown with 6AU at 50 g/ml for
120 min. This time point was selected based on a recent study in which the IMD2
steady-state mRNA levels of a large-scale 6AU screening of yeast deletion
mutants were analyzed (32).
RESULTS
A novel domain in Set2 mediates RNAPII interaction. Al-
though Set2 is known to bind to the phosphorylated CTD of
RNAPII, the region(s) within Set2 responsible for this associ-
ation is poorly defined (19, 21, 22, 33, 42). Thus, we generated
a series of Set2 mutant yeast expression constructs that con-
tained a C-terminal Flag epitope tag (Fig. 1A) and used them
in co-IP studies with antibodies generated against RNAPII.
Either full-length SET2, vector-only control, or the indicated
SET2 mutant was expressed in a set2 deletion mutant (set2),
and WCEs were prepared. As expected, immunoprecipitation
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of full-length Set2-Flag resulted in coprecipitation of RNAPII
as detected by immunoblotting with anti-phospho-CTD anti-
bodies (Fig. 1B). We previously reported that specific deletion
of the WW domain in Set2 does not disrupt Set2-RNAPII
coprecipitation, and so we hypothesized that the coiled-coil
region of Set2 may be responsible (42). Unexpectedly, we
found that a precise deletion of the coiled-coil region in Set2
(amino acids 548 to 618) did not disrupt this interaction (data
not shown), indicating that a previously undefined region in
Set2 mediates this association. As shown in Fig. 1B, we found
FIG. 1. Identification of a novel region in Set2 required for RNAPII binding. (A) Schematic representation of the Set2 constructs used to probe
for RNAPII interaction. The SET domain along with the AWS domain, postSET domain (PS), WW domain, and coiled-coil motif (CC) are shown.
All constructs contained a C-terminal Flag epitope. (B) set2 cells were transformed with either vector only or plasmids coding for the indicated
Set2-Flag construct, and WCE were prepared. WCE were immunoprecipitated with anti-Flag beads followed by immunoblotting with antibodies
directed against serine 5-phosphorylated CTD (H14; -Ser5P), serine 2-phosphorylated CTD (H5; -Ser2P), or the Flag epitope. Significant to
mention is that the H5 antibody may also recognize serine 5 CTD phosphorylation in addition to serine 2 phosphorylation (16). Asterisks indicate
the location of nonspecific Flag antibody-reactive species. (C) Schematic representation of the Set2-SRI domain constructs used to determine the
boundaries of the functional SRI domain. N- and C-terminal truncations of the SRI domain were made in 15-amino-acid increments as shown.
All constructs contained a C-terminal Flag epitope. (D) set2 cells were transformed with the indicated plasmids, WCE were prepared, and co-IPs
were performed using the antibodies indicated in panel B. Sizes of the molecular mass markers are shown.
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through further Set2 truncations that a region at the C termi-
nus of Set2, encompassing amino acid residues 619 to 733, is
both necessary and sufficient to mediate the interaction of Set2
with RNAPII (compare last two lanes). We therefore termed
this region the SRI domain.
We next sought to determine the precise boundaries of the
SRI domain. To accomplish this, we generated additional Set2
constructs containing N- and C-terminal truncations of the SRI
region (Fig. 1C) and used them in co-IP analyses as described
for Fig. 1B. Results revealed that N-terminal truncation of the
SRI domain beyond Set2 amino acid 619 abolished RNAPII
binding. However, binding was still possible with a C-terminal
truncation up to amino acid 718 of Set2 (Fig. 1D), thereby
identifying the boundaries of the SRI domain as amino acids
619 to 718.
Due to the possibility that the observed interaction between
the SRI domain and RNAPII shown in Fig. 1 might have been
influenced by the high levels of recombinant Set2 protein pro-
duced (as these constructs are expressed from a plasmid using
the highly active ADH1 promoter), we genomically tagged Set2
at amino acid 733 or 618 with a triple Flag sequence and
reexamined its association with RNAPII. As shown in Fig. 2A,
full-length Set2 (Set2-3Flag) again coimmunoprecipitated
RNAPII as analyzed by immunoblot analysis with the anti-
phospho-CTD antibodies. In contrast, a form of Set2 with the
SRI domain deleted [Set2(1-618)-3Flag] resulted in the aboli-
tion of RNAPII interaction. We also confirmed these results by
examining the protein associations of Set2 by affinity purifica-
tion, which revealed that the readily detectable subunits of
RNAPII (Rpb1 and Rpb2) were only observed in purifications
involving full-length Set2 (Fig. 2B). Additionally, while Rpb1
and Rpb2 were detected by mass spectrometry in gel excised
bands from the full-length Set2 purification, these proteins
were not detected in a parallel gel region excised from the form
of Set2 with the SRI domain deleted (data not shown). Col-
lectively, these data confirm the importance of the SRI domain
in mediating the Set2-RNAPII interaction.
The SRI domain of Set2 is conserved and interacts with the
phosphorylated CTD in vitro. Previous studies have suggested
that Set2 association with RNAPII is dependent, in part, on
the Paf1 transcription elongation complex (12, 19). Thus, it was
a formal possibility that the SRI domain linked Set2 to the
polymerase by indirect protein association. To test whether the
SRI domain of Set2 is responsible for direct association with
the CTD of RNAPII, we generated a variety of MBP fusions of
Set2 and examined their ability to associate with a recombinant
GST-CTD fusion protein that was either unmodified (GST-
yCTD) or phosphorylated by CTDK-I (GST-yPCTD). Using a
reverse far Western approach (see reference 31), the GST-
CTD fusions were resolved by SDS-PAGE, transferred to ni-
trocellulose, and then probed with MBP fusion proteins car-
rying full-length Set2 or only the SRI domain of Set2 [Set2(619-
733)]. Results revealed that both the full-length form of Set2
and the SRI domain of Set2 preferentially bound to the phos-
phorylated CTD (Fig. 3A). To independently confirm this in-
teraction and further address whether other regions of Set2
may bind to the phosphorylated CTD in vitro, we transferred
increasing amounts of MBP fusions of Set2 lacking the SRI or
containing only the SRI domain [Set2(1-618) and Set2(619-733),
respectively] to nitrocellulose and probed with a CTDK-I-
phosphorylated GST-[32P]CTD fusion. As shown in Fig. 3B,
this far Western approach revealed that while the SRI domain
of Set2 bound efficiently to the GST-[32P]CTD fusion, Set2
lacking the SRI domain did not. While Fig. 3B shows a 3.5-h
exposure, it is noteworthy that a 90-h exposure revealed a
potential weak interaction of Set2(1-618) to phosphorylated
CTD (data not shown); however, it is unclear whether such
interaction is physiologically relevant (Fig. 2 to 4) (31). In
summary, our results show that the SRI domain in Set2 binds
directly to the phospho-CTD of RNAPII. Thus, the ability of
the Paf1 complex to modulate Set2 activity is likely an indirect
consequence of the fact that this complex can regulate CTD
phosphorylation (28).
Next, we examined the specificity of the SRI domain for
binding phospho-epitopes by BIACORE analysis with three-
repeat synthetic CTD peptides that were phosphorylated in
each repeat at either Ser2 (2-phospho), Ser5 (5-phospho), or
both (2  5-phospho). As a control, a Ser-phosphorylated
peptide that mimics the charge state of the 2  5-phospho
peptide (6PC) was included. Sensor chips containing these
CTD peptides were reacted with the SRI domain of Set2
[Set2(619-733)], and binding was monitored. Surprisingly, we
found that the Set2 SRI domain bound preferentially to CTD
repeats that were doubly phosphorylated (Fig. 3C, compare 2
 5-phospho curve with 2-phospho and 5-phospho curves).
Moreover, because these response curves were obtained after
FIG. 2. The SRI domain is required for interaction of Set2 with
RNAPII. (A) Yeast strains containing full-length Set2 (Set2-3Flag) or
a form of Set2 without the SRI domain [Set2(1-618)-3Flag] were made
via genomic tagging with the 3xFlag epitope. WCEs of these strains
were immunoprecipitated with anti-Flag beads followed by immuno-
blotting with antibodies directed against serine 2-phosphorylated CTD
(H5; -Ser2P), serine 5-phosphorylated CTD (H14; -Ser5P), or the
Flag epitope. Sizes of the molecular mass markers are shown, and
asterisks indicate the location of expected Set2-Flag products.
(B) WCEs from the strains in panel A were incubated with anti-Flag
resin, and the resulting bound proteins were eluted with 3xFlag pep-
tide. Eluted proteins were resolved by a 4-to-12% NuPAGE gel and
examined by Coomassie staining. Arrows indicate the protein identity
of bands in the Set2-3Flag lane that were examined by mass spectrom-
etry, while analysis of parallel regions in the Set2(1-618)-3Flag lane was
negative for the presence of Rpb1 or Rpb2. Sizes of the molecular
mass markers are shown.
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subtracting the contribution of the nonspecific control peptide
(6PC), this binding depends on the presence of both Ser2P and
Ser5P in the context of the CTD heptad repeat sequence.
Based on additional BIACORE experiments involving titrated
amounts of the Set2 SRI domain (not shown), we determined
that the Set2 SRI domain binds to the 2  5-phospho peptide
(relative to the control) with an apparent dissociation constant
of about 6 M. It is important to note that the ability of the
SRI domain to bind to the nonspecific control peptide was
nearly equivalent to that found for binding to the individually
phosphorylated peptides (data not shown). We take this result
to suggest that the SRI domain of Set2 has a specific require-
ment for Ser2- and Ser5-phosphorylated CTD epitopes. Col-
lectively, these results reveal a novel and selective requirement
for a specific CTD phosphorylation pattern in Set2 binding to
RNAPII.
Given these findings, we next asked whether the SRI domain
of Set2 is a conserved phospho-CTD-binding motif found in
other proteins in budding yeast and beyond. By performing a
PSI-BLAST search, we determined that the SRI domain of
Set2 was unique to this enzyme alone in budding yeast (data
not shown). However, the SRI domain showed significant ho-
mology to the C-terminal regions of proteins in other species
that also displayed domain organizations similar to that of Set2
(AWS, SET, postSET, and WW), suggesting that these pro-
teins may be the functional homologs of budding yeast Set2
and function with RNAPII (Table 1). Interestingly, the pro-
teins identified in Table 1 represent only a subset of proteins
that the SMART database revealed to contain AWS, SET, and
postSET domains (	70), suggesting that not every putative
histone methyltransferase that contains an AWS, SET, and
postSET is by default a functional homolog of Set2. Indeed,
recent evidence shows that the Drosophila melanogaster Ash1
protein, which falls into the Set2 family of HMTs (by way of
having an AWS domain rather than an archetypal PreSET
domain), is an H3 lysine 4 methyltransferase (4, 6). These
results suggest that the SRI domain is a probable indicator of
RNAPII-interacting enzymes that catalyze K36 methylation.
To determine whether any of the putative SRI domains we
identified by our PSI-BLAST search would actively bind to the
phospho-CTD, we expressed and purified from bacteria a GST
fusion protein carrying the C-terminal 178 residues of the
human Huntington interacting protein B (HYPB) that in-
cludes the region of homology to Set2’s SRI domain (Table 1).
Using the far Western approach as described for Fig. 3B, we
found that similar to Set2, the SRI-containing region in HYPB
interacts efficiently with a CTDK-I-phosphorylated GST-
[32P]CTD fusion (data not shown). Furthermore, additional
BIACORE analyses (as described for Fig. 3C) revealed that
the human SRI domain displays binding properties nearly
identical to those of the budding yeast domain (H. P. Phatnani,
A. L. Greenleaf, and P. Zhou, unpublished results). Taken
FIG. 3. The SRI domain of Set2 binds synergistically to doubly
modified CTD repeats. (A) Reverse far Western analysis. GST-yCTD
and CTDK-I-phosphorylated GST-CTD (GST-yPCTD) fusion pro-
teins were subjected to SDS-PAGE and transferred to nitrocellulose.
Membranes were probed individually with purified recombinant full-
length MBP-Set2 (Set2) or with MBP-SRI [Set2(619-733)], and the
bound MBP fusions were detected with an anti-MBP antibody. As a
control, a duplicate membrane was probed with an anti-GST antibody
(-GST) to demonstrate the presence of both GST-CTD fusion proteins.
(B) Increasing amounts of two MBP fusion proteins [Set2(1-618) and
Set2(619-733)] were resolved in two SDS-polyacrylamide gels; one gel was
subjected to far Western analysis with GST-[32P]CTD as a probe, and the
other was stained with Coomassie. (C) BIACORE analysis of the SRI
domain. The MBP-SRI fusion protein [MBP-Set2(619-733)] was analyzed
by surface plasmon resonance (BIACORE) for binding to distinct phos-
phorylated synthetic three-repeat CTD peptides. These peptides were
either Ser5 phosphorylated (5-phospho), Ser2 phosphorylated (2-phos-
pho), or both (2  5-phospho) in each repeat (see Materials and Meth-
ods). Response units, on the y axis, represent binding to the peptides. The
binding response to a scrambled control peptide carrying six SerPO4
residues (see Materials and Methods) has been subtracted from each
of the three response curves. Only the peptide carrying both Ser2PO4
and Ser5PO4 in each repeat showed binding above control levels, and
we estimate the affinity of this interaction (after subtraction of back-
ground binding to the control peptide) to be 6 M.
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FIG. 4. Deletion of the SRI domain in Set2 abolishes H3 K36 dimethylation. (A) Yeast nuclear extracts prepared from set2 cells or the
indicated genomically tagged strains in the BY4742 background were probed with antibodies against dimethylated lysine 36 at H3 [-Me2(Lys36)
H3] to monitor the role of the SRI domain in global K36 methylation levels. An antibody directed against the C terminus of H3 (-H3 C terminus)
was used as a loading control. Nuclear levels of Set2 in these strains were monitored using the anti-Flag antibody. A similar loss of K36 methylation
was observed when the SRI domain was genomically deleted in the W303 background (data not shown). (B) Full-length (Set2-Flag) or SRI
domain-truncated [Set2(1-618)-Flag] recombinant forms of Set2, which also contained an N-terminal MBP epitope, were prepared and analyzed for
their HMT activity in vitro. HMT reactions were prepared with bacterial lysates containing the indicated Set2 constructs with or without
nucleosomes. Identical samples were analyzed by the filter-binding assay (upper) and fluorography (middle). Immunoblotting with the Flag
antibody (lower) was performed to ensure equal amounts of protein were present in each reaction mixture. (C) WT or SRI-deleted yeast strains
were analyzed by ChIP for K36 dimethyl levels on genes. DNA isolated from the K36 methylation IPs was used in PCRs with primer pairs for the
indicated regions of the SCC2 gene (top). PCR products of the input DNA (input) and ChIP DNA (Me2K36) are shown (middle). The asterisks
indicate the location of a PCR product pertaining to an intergenic region at chromosome V (ChV), which was used as a loading control in all PCRs.
The histogram displays the relative enrichment values for K36 dimethylation (bottom). The values were calculated by dividing the ratio of band
intensities for IP DNA/ChV with the ratio of intensities for the input DNA/ChV. Identical results were found for the PMA1, ENO1, and ADH1
genes (data not shown).
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together, these results suggest that the SRI domain is a highly
conserved and novel phospho-CTD-interacting domain.
The SRI-RNAPII interaction is required for H3 K36 meth-
ylation. Given the conserved nature and potential importance
of the SRI domain to Set2’s cellular function, we next investi-
gated the consequences of deleting this domain. Although
studies suggest that the CTD and its proper phosphorylation
are necessary for K36 methylation, it has not been formally
excluded that the phospho-CTD might regulate the enzymatic
activity of Set2 (19, 21, 33, 42). To determine if the loss of the
SRI domain would result in a loss of genome-wide K36 meth-
ylation, we measured the K36 dimethylation levels in strains
containing WT Set2 or Set2 with the SRI domain genomically
deleted. Nuclei were prepared from these strains and then
resolved on an SDS-PAGE gel, followed by Western blotting
with an antibody specific to dimethylated K36. Results re-
vealed that deletion of the SRI domain in Set2 abolishes global
H3-K36 dimethylation (Fig. 4A). As a control, we examined
the levels of H3 in parallel gels with an antibody specific to the
C terminus of H3, which revealed that the levels of histones
were similar in both nuclei preparations. Importantly, the nu-
clei of both strains showed the presence of Set2 by Western
blot analysis using an anti-Flag antibody (Fig. 4A). This result
indicates that the deletion of the SRI domain does not influ-
ence the nuclear localization of Set2 or significantly affect its
stability. The requirement of the SRI domain for K36 methyl-
ation was independently confirmed in parallel studies in which
a different strain background (W303) was genomically tagged
either at the C terminus or at the beginning of the SRI domain
at residue 618 (data not shown). In addition, we used the ChIP
assay to analyze chromatin modifications at a gene-specific
resolution and also observed a loss of K36 methylation at the
SCC2 gene when the SRI domain of Set2 is removed (Fig. 4C).
Analysis of the PMA1, ENO1, and ADH1 genes yielded similar
results (data not shown).
To test the possibility that the SRI domain itself might reg-
ulate Set2’s catalytic activity, we analyzed recombinant full-
length Set2 or SRI-deleted MBP-Set2 fusion proteins in HMT
assays with chicken oligo-nucleosomes. Results showed that
both forms of the enzyme were equally active for K36 meth-
ylation, indicating that the SRI domain is not required for the
catalytic activity of Set2 in vitro (Fig. 4B). In fact, we found
that a region of Set2 encompassing the AWS, SET, and post-
SET domains (amino acid residues 1 to 261 in Set2) is fully
active for histone methylation in vitro, indicating that the C
terminus of Set2 does not intrinsically regulate its HMT activ-
ity (data not shown).
Set2 methylation influences transcription elongation and
RNAPII occupancy on genes. Growth phenotypes observed in
the presence of the drug 6AU are frequently used as indicators
of defects in transcription elongation (8, 23, 25, 41). We there-
fore asked whether deletion of SET2, or prevention of the
Set2-RNAPII association by deletion of the SRI domain,
would exhibit 6AU-dependent phenotypes. We began by ex-
amining the 6AU phenotypes caused by Set2 deletion in sev-
eral strain backgrounds. Various WT (W303, BY4742/SC288C,
and YCB652) and matched set2 strains were grown on con-
trol medium (no drug) or medium containing 6AU. The parent
strain YCB652 contained the integrated URA3 gene, which is
required for the 6AU assay, while others were transformed
with the URA3 plasmid pRS316 (38). The survival and colony
sizes of each strain were monitored after several days of growth
and compared to those on control plates. As shown in Fig. 5A,
we found that deletion of SET2 in these strain backgrounds
resulted in a significant resistance phenotype to 6AU. Similar
results were also observed when we used medium containing
mycophenolic acid, another drug that reveals elongation de-
fects but through a mechanism unique from that of 6AU (data
not shown). Furthermore, we analyzed a dst1 null strain of the
BY4742 background and observed the characteristic 6AU sen-
sitivity known to exist for this mutant (Fig. 5A) (3, 30, 41).
Given that previous studies have demonstrated that a proper
response to 6AU is the induced expression of the IMD2 gene,
which is a result of the elongation machinery’s response to
depleted nucleotide pools (35), we sought to verify that the
resistance phenotype observed in the set2 deletion mutant
was not due to an aberrant effect on the cellular metabolism of
6AU. Using semiquantitative RT-PCR, we monitored the ex-
pression levels of IMD2 and SNR6 (an RNAPIII-transcribed
gene used as a control) in the presence or absence of 6AU. As
shown in Fig. 5B, we found that the expression of the IMD2
gene was increased to equal degrees in both WT and set2
strains in the presence of the drug, confirming that the loss of
Set2 results in a bona fide transcription elongation defect.
Importantly, the IMD2 gene was not induced in the absence of
6AU for either the WT or set2 strains, indicating that Set2
does not act to repress the basal expression of this gene (Fig.
5B). In addition to our results with Set2, 6AU resistance has
also been observed from the deletion or mutation of a variety
TABLE 1. Putative Set2 homologs identified by PSI-BLAST searching with the SRI domain
Species Gene namea GI accession Sequence position ofputative SRI domain
% Identity/similarity to
SRI domainb
S. cerevisiae Set2 6322293 619–718 NA
Candida albicans Ca019.9324 46435920 723–820 35/55
Homo sapiens HYPB 30410779 1956–2056 23/37
Mus musculus XP_135176 38090181 2393–2493 23/37
D. melanogaster CG1716 24641786 2262–2356 21/39
Neurospora crassa XP_322355 32403484 569–653 19/37
S. pombe SPAC29B12 2408044 703–778 17/42
a All proteins identified contain a domain architecture similar to yeast Set2, including the AWS, SET, postSET and, in some cases, WW domains. It is notable that
the putative SRI domains, as with Set2, are found in the C termini of these proteins.
b Identity refers to the percentage of identical amino acids present between the yeast Set2 SRI domain and the putative SRI domain of the indicated homolog, while
similarity indicates amino acid replacements that exhibit similar charge or hydrophobicity.
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FIG. 5. Deletion of SET2 results in an elongation phenotype and an alteration of RNAPII occupancy on genes. (A) Various strains containing
either WT, set2, or dst1 alleles were plated on synthetic dextrose-uracil medium with or without 6AU (100 g/ml) and grown at 30°C for 2 to
3 days to monitor for transcription elongation phenotypes. All strains contained the plasmid pRS316 containing the URA3 gene, except yeast strain
YCB652, which contains an integrated URA3 gene. Results using mycophenolic acid (100 g/ml) were found to yield identical results (data not
shown). (B) The loss of Set2 does not aberrantly affect the increased expression of IMD2 in 6AU. Semiquantitative RT-PCR was used to monitor
the expression of IMD2 and SNR6 (a polymerase III-transcribed gene used as a control) in WT or set2 strains in the absence or presence of 6AU
(50 g/ml). The results of RT-PCRs with (PCR amplification cycles indicated above) or without (-RT) reverse transcriptase are shown. The fold
change in IMD2 expression under each condition is indicated, based on averages of the three cycling parameters for each strain, with WT set to
1.0 as reference. (C) WT or set2 strains were analyzed by ChIP for RNAPII levels. Isolated DNA from the RNAPII IPs were used in PCRs with
primer pairs for regions of SCC2 as indicated in the schematic. The data shown represent the average of 13 individual ChIP assays from separate
cell pellets. The standard error of the mean is indicated. Asterisks indicate the relative set2 RNAPII enrichment values that were statistically
significant compared to their WT counterparts (P 
 0.01 for primer set D and P 
 0.001 for primer sets E and F). ChIP analyses using other
RNAPII antibodies (8GW16 from Covance or Rpb3 from NeoClone) or the N terminus of Rpb1 (y-80; Santa Cruz) revealed the same pattern
of RNAPII distribution as displayed in the figure (results not shown). (D) SCC2 expression was not changed in set2 despite the increase in
RNAPII density detected by ChIP. The expression levels of SCC2 and SNR6 (control) were monitored by semiquantitative RT-PCR as described
for panel B. The fold change of SCC2 expression in set2 cells compared to that in WT is displayed as described for panel C.
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of other elongation factors, including Chd1, Bye1, Isw1, and
forkhead factor 1 (2, 40, 41).
Since transcription elongation defects are typically corre-
lated with changes in the occupancy and distribution of
RNAPII along genes, we therefore asked whether the loss of
Set2 would result in an alteration in RNAPII levels on actively
transcribed genes. Using an antibody that recognizes the gen-
eral levels of RNAPII irrespective of its phosphorylation status
(34), we examined RNAPII levels on the promoters and coding
regions of active genes in WT and set2 strains by ChIP. As
shown in Fig. 5C, we found that RNAPII levels in the set2
deletion mutant were significantly increased in the middle to
late coding region of the actively transcribing SCC2 gene com-
pared to the WT control strain. Interestingly, the gene loca-
tions that showed an RNAPII increase were also the same
locations determined to be highly methylated by Set2 (Fig. 4C),
suggesting the possibility that a relationship may exist between
regions of chromatin highly methylated at K36 and RNAPII
occupancy potential. We next examined a variety of other
active genes in the set2 deletion mutant to determine how
general this RNAPII defect would be. We examined the pro-
moter and coding regions of TOM1, MDN1, PMA1, ENO1, and
FIR1 for the presence of RNAPII as described above and
found a similar pattern of RNAPII increase in the set2 deletion
mutant as was observed for SCC2 (data not shown). We ad-
dressed the possibility that the observed increases in RNAPII
might be a result of a general increase in transcript formation
for these genes in the absence of Set2. Indeed, Set2 has been
shown to play a role in the basal repression of GAL4 (20). We
therefore examined the expression of the genes indicated
above by semiquantitative RT-PCR and observed that the in-
creased density of RNAPII did not correlate with any change
in the steady-state mRNA levels (Fig. 5D and data not shown).
These mRNA results were also confirmed independently by
examining the gene expression microarray profiles found in
WT and set2 cells (N. Krogan and J. Greenblatt, personal
communication). Furthermore, we also examined TBP levels
by ChIP at the promoters of several genes listed above (SCC2
and TOM1) and found no significant increases in TBP occu-
pancy in the set2 deletion mutant (data not shown). Our data
indicate that Set2 does not function as a basal repressor of the
genes analyzed, but rather it affects the precise levels of
RNAPII on genes, further supporting the 6AU results suggest-
ing that Set2 can influence RNAPII elongation.
The above results suggest Set2 is important for transcription
elongation, but they do not reveal whether this function of Set2
is dependent on its association with RNAPII and/or K36 meth-
ylation. To test if loss of the interaction between Set2 and
RNAPII is responsible for the elongation defect, we assayed
the growth of strains with SRI deleted [Set2(1-618)-3Flag],
SET2 deleted, and the Set2-3Flag strains by using 6AU. We
observed that deletion of the SRI domain resulted in a resis-
tance to 6AU that was similar to that of the set2 deletion
mutant, indicating that the interaction between Set2 and
RNAPII is necessary for the normal transcription elongation
functions of Set2 (Fig. 6A).
We next asked whether K36 methylation per se is important
for the activity of Set2 in this process. In one case, we trans-
formed set2 cells with a plasmid coding for either full-length
Set2 (SET2) or a form of Set2 containing a point mutation
(set2R195G) that has been shown to abolish K36 methylation
activity in vitro and in vivo (39). We found that expression of
SET2 in the set2 strain nearly restored WT levels of 6AU
sensitivity (Fig. 6B). However, set2 cells expressing set2R195G
FIG. 6. K36 methylation influences transcription elongation.
(A) Genomically tagged strains containing either full-length Set2
(Set2-3Flag) or Set2 with the SRI domain deleted [Set2(1-618)-3Flag]
were generated and assayed, as in Fig. 5A, for growth on 6AU and
compared to WT and set2 strains. (B) set2 strains were transformed
with a plasmid expressing WT Set2 (SET2) or a mutant form of Set2
which abolishes its catalytic activity (set2R195G) and assayed for growth on
6AU as before. (C) Yeast strains (WZY42 derived) bearing various point
mutations on histone H3 were assayed for growth on 6AU as in Fig. 5A.
(D) WT or a K36 mutated strain was analyzed by ChIP for RNAPII levels
for the SCC2 gene, as in Fig. 5C. The histogram data are representative
of two independent experiments which showed similar results.
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showed resistance to the drug (Fig. 6B), consistent with a role
for K36 methylation in the elongation process. In the second
case, we asked whether amino acid substitutions at K36 that
prevent methylation (K36A and K36R) would result in resis-
tance to 6AU and RNAPII density increases. As shown in Fig.
6C, the K36A and K36R strains were significantly resistant to
6AU compared to the WT H3 strain, whereas strains with
mutations at other sites of methylation (K4 and K79) or sites of
phosphorylation (serine 10) were not. In addition, the 6AU
resistance caused by the K36A or K36R mutations was not
suppressed by mutation of lysine 4 (Fig. 6C, K4R/K36R). Sig-
nificantly, we also found the same pattern of increased
RNAPII density for the SCC2 gene in the K36A strain as with the
set2 strain (Fig. 6D), suggesting that the specific lack of K36
methylation is the primary cause of the 6AU phenotype and
RNAPII defect. These data strongly implicate the methylation by
Set2 as being functionally important in the elongation process.
DISCUSSION
Recent work in S. cerevisiae has revealed an unexpected role
for the Set1 and Set2 histone methyltransferases in transcrip-
tion elongation. Although Set2 associates with the elongating
polymerase, very little is known regarding the influence of Set2
or K36 methylation on transcription elongation. Our results
presented in this study reveal that (i) a novel region of Set2,
which we have termed the SRI domain, is necessary and suf-
ficient for the functional interaction between Set2 and
RNAPII; (ii) the Set2-RNAPII interaction, established
through the SRI domain, is required for H3 K36 methylation;
and (iii) the K36 methylation mediated by Set2, in particular,
influences RNAPII elongation.
A novel phospho-CTD binding motif in Set2. Based on re-
cent observations of other RNAPII CTD-interacting proteins,
we expected that the WW and/or coiled-coil regions in Set2
would mediate its association with RNAPII. Surprisingly, nei-
ther of these domains was found to be involved in RNAPII
binding. Instead, a region from 619 to 733 in Set2, which we
have termed the SRI domain, was found to be both necessary
and sufficient for the Set2-RNAPII interaction (Fig. 1 to 3).
This is in conflict with an earlier report which stated that the
WW domain of Set2 is required for the association of this
enzyme with RNAPII (22). However, the technical approach
used in this earlier study to analyze the involvement of the WW
domain in RNAPII interaction employed a genomic insertion
of the TAP tag in front of the WW domain of Set2, which
removed its entire C terminus, including the SRI domain. Even
though the WW and/or coiled-coil regions in Set2 are not likely
to be involved in its association with RNAPII, they may play
important roles in Set2 function by mediating the association
of Set2 with other phosphorylated proteins and/or itself since
Set2 is thought to exist as a homodimer in the cell (33, 39).
Through further examination of the binding requirements of
the SRI domain, we uncovered that this domain binds prefer-
entially to the CTD phosphorylated at both serines 2 and 5,
compared to the singly phosphorylated form or a charge con-
trol peptide (Fig. 3C). This discovery strongly suggests that a
synergistic relationship between CTD phosphorylation and
Set2 binding exists. Interestingly, Ser2 phosphorylation is pre-
dominantly found in the body of genes, while it has been
thought that Ser5 phosphorylation is generally restricted to the
promoters and 5 region of these same genes. Recent studies,
however, reveal that Ser5 phosphorylation is indeed found at
significant levels throughout the transcribed regions of genes
(1). Furthermore, a recent paper has noted that CTDK-I pref-
erentially phosphorylates serine 2 of the heptad repeat only
when the serine 5 position is already phosphorylated (16).
Thus, it seems likely that doubly phosphorylated CTD epitopes
exist in yeast that may serve to direct the interaction of Set2
(and perhaps other phospho-CTD-interacting proteins).
Based on our BLAST search analysis, the SRI domain ap-
pears to be conserved in other organisms only in proteins that
have a domain architecture nearly identical to that of Set2
(those containing AWS or SAC, SET, Post-SET, and WW)
(Table 1). We take these data to suggest that the SRI domain
is a probable indicator of proteins that are bona fide functional
homologs of Set2. Consistent with this, we have determined
that a construct containing the SRI region of HYPB (Table 1)
binds directly to the phosphorylated CTD. Furthermore, our
studies also reveal the putative S. pombe homolog of Set2
(Table 1) to be a robust K36 HMT that also interacts with
RNAPII (S. A. Morris and B. D. Strahl, unpublished data).
Based on these observations, it is likely that Set2 and K36
methylation have a conserved function in transcription elon-
gation.
Role for H3 K36 methylation in transcription elongation.
Previous studies have implicated Set2 in the transcription elon-
gation process. This has been established not only by the nu-
merous biochemical and genetic analyses that have been per-
formed on Set2, but also by the use of 6AU, a drug commonly
used as an indicator for elongation defects. The compound
6AU depletes the available nucleotide pool by inhibition of the
enzyme IMP dehydrogenase, which is responsible for cata-
lyzing the rate-limiting step in de novo synthesis of GTP (8, 14,
15). Inhibition of IMP dehydrogenase results in a challenge to
the transcription elongation machinery, which is continually in
need of free nucleotides. Thus, strains with altered transcrip-
tion elongation function display a sensitivity to the drug dif-
ferent from their WT parent strain. Our 6AU assays revealed
that set2 deletion mutants or deletion of the SRI domain itself
results in resistance to the drug, whether the URA3 gene is
genomically inserted or carried ectopically on a plasmid (Fig.
5A). This is in contrast to some previous studies that showed
that set2 mutants are modestly sensitive to 6AU (19, 22, 33).
While it is unclear why varied 6AU results have been reported,
it is noteworthy that others have also seen a 6AU resistance
phenotype with set2 deletion mutants (21, 43; D. Stillman,
personal communication), indicating that the differences may
lie in context-specific differences in the genetic backgrounds
used.
In addition to set2 deletion, resistance to 6AU has also been
observed in strains mutated for a number of other factors,
including Ess1, Bye1, Chd1, Isw1, and Fkh1 (2, 40, 41). Many
of these factors have been shown to influence transcription
elongation via regulation of specific phases in the transcription
elongation cycle, such as the transition between elongation and
initiation or termination (24, 25, 41). While 6AU phenotypes
alone are not sufficient to allow conclusions regarding the
mechanistic details of how a protein affects the elongation
phase of transcription, 6AU resistance can be interpreted as a
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consequence of increased elongation efficiency resulting from
the deletion of a factor which negatively regulates elongation.
Indeed, it was found that strains with the Ess1 suppressor,
Bye1, deleted displayed resistance to 6AU, and this protein
may negatively regulate transcription elongation by inducing
RNAPII pausing at elongation arrest sites (41). In addition,
Chd1 null strains were found to exhibit 6AU resistance, which
may be due to an indirect effect on elongation by its influence
on termination (2, 40).
In an effort to better understand the nature of the 6AU
phenotype of the set2 deletion mutant, we examined the dis-
tribution of RNAPII along genes. Interestingly, we found that
RNAPII levels significantly increased at the 3 ends of genes in
the absence of Set2 or when methylation was inhibited (Fig. 5C
and 6D). Furthermore, this increase generally paralleled K36
methylation levels, indicating the possibility of a direct mech-
anistic link between the levels of K36 methylation and RNAPII
occupancy (Fig. 4C and 5C). While our results strongly impli-
cate K36 methylation as having a direct role in RNAPII elon-
gation, the precise role is currently unclear. We propose three
possibilities: (i) K36 methylation generates a chromatin struc-
ture that is more permissive for RNAPII passage. In this sce-
nario, the loss of Set2/K36 methylation would result in a chro-
matin structure that is more difficult for RNAPII to pass, which
might appear as an increase in RNAPII occupancy along the
gene through increased pausing. (ii) K36 methylation gener-
ates chromatin structure that is less permissive for RNAPII
passage. In this case, K36 methylation acts as a negative reg-
ulator of RNAPII elongation, and the loss of this “mark”
permits increased RNAPII passage. However, since the termi-
nation event at the 3 end would be under tight checkpoint
control and would be rate limiting, the loss of K36 methylation
would result in a buildup or backlog of RNAPII across the
gene, while overall transcript production remained consistent.
Such a buildup of RNAPII might be viewed as advantageous to
cells when presented with 6AU stress. Finally, (iii) termination
efficiency is diminished in the absence of K36 methylation.
Thus, similar to chd1 mutants, the reduced efficiency of termi-
nation would result in a backlog of RNAPII across the gene.
Among these possibilities, we suggest scenario ii is most likely,
given the 6AU resistance of set2 strains and the fact that
other factors whose deletion results in 6AU resistance have
been shown to be negative regulators of RNAPII elongation.
In summary, our results provide strong evidence that K36
methylation, mediated by the SRI-dependent association of
Set2 with RNAPII, plays a role in the elongation phase of
transcription. Whether Set2’s elongation role is mediated
through the association of factors that bind to K36 methyl-
ation, or through the ability of this modification to control
chromatin structure by regulating nucleosome-nucleosome or
nucleosome-DNA interactions, is unknown but will be of keen
interest for future studies.
ACKNOWLEDGMENTS
This work is supported by NIH grants GM068088 (B.D.S.) and
GM40505 (A.G.) and a grant from the American Heart Association
(0465506U) to B.D.S. B.D.S. is a Pew Scholar in the Biomedical
Sciences.
We thank C. D. Allis for providing the H3 S10A mutant plasmid, D.
Bentley for providing the CTD antibody used for ChIP, S. Dent for
providing the H3/H4 shuffle strain WZY42 and plasmids, M. Green for
the TBP antiserum, M. MacDonald for the original HYPB clone, and
T. Tsukiyama for the p3Flag-KanMX plasmid. We are grateful to J.
Greenblatt, N. Krogan, and D. Stillman for sharing unpublished results
as well as B. Temple for assistance in BLAST database searches. We
also thank J. Lieb, M. Hall, G. Sancar, and Strahl lab members for
helpful discussions and comments on the manuscript, as well as M.
Hall for mass spectrometry analysis.
REFERENCES
1. Ahn, S. H., M. Kim, and S. Buratowski. 2004. Phosphorylation of serine 2
within the RNA polymerase II C-terminal domain couples transcription and
3 end processing. Mol. Cell 13:67–76.
2. Alen, C., N. A. Kent, H. S. Jones, J. OSullivan, A. Aranda, and N. J.
Proudfoot. 2002. A role for chromatin remodeling in transcriptional termi-
nation by RNA polymerase II. Mol. Cell 10:1441–1452.
3. Archambault, J., F. Lacroute, A. Ruet, and J. D. Friesen. 1992. Genetic
interaction between transcription elongation factor TFIIS and RNA poly-
merase II. Mol. Cell. Biol. 12:4142–4152.
4. Beisel, C., A. Imhof, J. Greene, E. Kremmer, and F. Sauer. 2002. Histone
methylation by the Drosophila epigenetic transcriptional regulator Ash1.
Nature 419:857–862.
5. Briggs, S. D., M. Bryk, B. D. Strahl, W. L. Cheung, J. K. Davie, S. Y. Dent,
F. Winston, and C. D. Allis. 2001. Histone H3 lysine 4 methylation is medi-
ated by Set1 and required for cell growth and rDNA silencing in Saccharo-
myces cerevisiae. Genes Dev. 15:3286–3295.
6. Byrd, K. N., and A. Shearn. 2003. ASH1, a Drosophila trithorax group
protein, is required for methylation of lysine 4 residues on histone H3. Proc.
Natl. Acad. Sci. USA 100:11535–11540.
7. Edmondson, D. G., M. M. Smith, and S. Y. Roth. 1996. Repression domain
of the yeast global repressor Tup1 interacts directly with histones H3 and H4.
Genes Dev. 10:1247–1259.
8. Exinger, F., and F. Lacroute. 1992. 6-Azauracil inhibition of GTP biosyn-
thesis in Saccharomyces cerevisiae. Curr. Genet. 22:9–11.
9. Gelbart, M. E., T. Rechsteiner, T. J. Richmond, and T. Tsukiyama. 2001.
Interactions of Isw2 chromatin remodeling complex with nucleosomal arrays:
analyses using recombinant yeast histones and immobilized templates. Mol.
Cell. Biol. 21:2098–2106.
10. Gerber, M., and A. Shilatifard. 2003. Transcriptional elongation by RNA
polymerase II and histone methylation. J. Biol. Chem. 278:26303–26306.
11. Hampsey, M., and D. Reinberg. 2003. Tails of intrigue: phosphorylation of
RNA polymerase II mediates histone methylation. Cell 113:429–432.
12. Henry, K. W., A. Wyce, W. S. Lo, L. J. Duggan, N. C. Emre, C. F. Kao, L.
Pillus, A. Shilatifard, M. A. Osley, and S. L. Berger. 2003. Transcriptional
activation via sequential histone H2B ubiquitylation and deubiquitylation,
mediated by SAGA-associated Ubp8. Genes Dev. 17:2648–2663.
13. Hsu, J. Y., Z. W. Sun, X. Li, M. Reuben, K. Tatchell, D. K. Bishop, J. M.
Grushcow, C. J. Brame, J. A. Caldwell, D. F. Hunt, R. Lin, M. M. Smith, and
C. D. Allis. 2000. Mitotic phosphorylation of histone H3 is governed by
Ipl1/aurora kinase and Glc7/PP1 phosphatase in budding yeast and nema-
todes. Cell 102:279–291.
14. Hyle, J. W., R. J. Shaw, and D. Reines. 2003. Functional distinctions between
IMP dehydrogenase genes in providing mycophenolate resistance and gua-
nine prototrophy to yeast. J. Biol. Chem. 278:28470–28478.
15. Jackson, R. C., G. Weber, and H. P. Morris. 1975. IMP dehydrogenase, an
enzyme linked with proliferation and malignancy. Nature 256:331–333.
16. Jones, J. C., H. P. Phatnani, T. A. Haystead, J. A. MacDonald, S. M. Alam,
and A. L. Greenleaf. 2004. C-terminal repeat domain kinase I phosphorylates
Ser2 and Ser5 of RNA polymerase II C-terminal domain repeats. J. Biol.
Chem. 279:24957–24964.
17. Komarnitsky, P., E. J. Cho, and S. Buratowski. 2000. Different phosphory-
lated forms of RNA polymerase II and associated mRNA processing factors
during transcription. Genes Dev. 14:2452–2460.
18. Krogan, N. J., J. Dover, A. Wood, J. Schneider, J. Heidt, M. A. Boateng, K.
Dean, O. W. Ryan, A. Golshani, M. Johnston, J. F. Greenblatt, and A.
Shilatifard. 2003. The Paf1 complex is required for histone H3 methylation
by COMPASS and Dot1p: linking transcriptional elongation to histone
methylation. Mol. Cell 11:721–729.
19. Krogan, N. J., M. Kim, A. Tong, A. Golshani, G. Cagney, V. Canadien, D. P.
Richards, B. K. Beattie, A. Emili, C. Boone, A. Shilatifard, S. Buratowski,
and J. Greenblatt. 2003. Methylation of histone H3 by Set2 in Saccharomyces
cerevisiae is linked to transcriptional elongation by RNA polymerase II. Mol.
Cell. Biol. 23:4207–4218.
20. Landry, J., A. Sutton, T. Hesman, J. Min, R. M. Xu, M. Johnston, and R.
Sternglanz. 2003. Set2-catalyzed methylation of histone H3 represses basal
expression of GAL4 in Saccharomyces cerevisiae. Mol. Cell. Biol. 23:5972–
5978.
21. Li, B., L. Howe, S. Anderson, J. R. Yates III, and J. L. Workman. 2003. The
Set2 histone methyltransferase functions through the phosphorylated car-
boxyl-terminal domain of RNA polymerase II. J. Biol. Chem. 278:8897–8903.
22. Li, J., D. Moazed, and S. P. Gygi. 2002. Association of the histone methyl-
VOL. 25, 2005 A NOVEL CTD-INTERACTING DOMAIN LINKS Set2 TO RNAPII 3315
transferase Set2 with RNA polymerase II plays a role in transcription elon-
gation. J. Biol. Chem. 277:49383–49388.
23. Mandal, S. S., H. Cho, S. Kim, K. Cabane, and D. Reinberg. 2002. FCP1, a
phosphatase specific for the heptapeptide repeat of the largest subunit of
RNA polymerase II, stimulates transcription elongation. Mol. Cell. Biol.
22:7543–7552.
24. Morillon, A., N. Karabetsou, J. O’Sullivan, N. Kent, N. Proudfoot, and J.
Mellor. 2003. Isw1 chromatin remodeling ATPase coordinates transcription
elongation and termination by RNA polymerase II. Cell 115:425–435.
25. Morillon, A., J. OSullivan, A. Azad, N. Proudfoot, and J. Mellor. 2003.
Regulation of elongating RNA polymerase II by forkhead transcription
factors in yeast. Science 300:492–495.
26. Morris, D. P., J. M. Lee, D. E. Sterner, W. J. Brickey, and A. L. Greenleaf.
1997. Assaying CTD kinases in vitro and phosphorylation-modulated prop-
erties of RNA polymerase II in vivo. Methods 12:264–275.
27. Morris, D. P., H. P. Phatnani, and A. L. Greenleaf. 1999. Phospho-carboxyl-
terminal domain binding and the role of a prolyl isomerase in pre-mRNA
3-end formation. J. Biol. Chem. 274:31583–31587.
28. Mueller, C. L., S. E. Porter, M. G. Hoffman, and J. A. Jaehning. 2004. The
Paf1 complex has functions independent of actively transcribing RNA poly-
merase II. Mol. Cell 14:447–456.
29. Ng, H. H., F. Robert, R. A. Young, and K. Struhl. 2003. Targeted recruitment
of Set1 histone methylase by elongating Pol II provides a localized mark and
memory of recent transcriptional activity. Mol. Cell 11:709–719.
30. Orphanides, G., W. H. Wu, W. S. Lane, M. Hampsey, and D. Reinberg. 1999.
The chromatin-specific transcription elongation factor FACT comprises hu-
man SPT16 and SSRP1 proteins. Nature 400:284–288.
31. Phatnani, H. P., J. C. Jones, and A. L. Greenleaf. 2004. Expanding the
functional repertoire of CTD kinase I and RNA polymerase II: novel phos-
phoCTD-associating proteins in the yeast proteome. Biochemistry 43:15702–
15719.
32. Riles, L., R. J. Shaw, M. Johnston, and D. Reines. 2004. Large-scale screen-
ing of yeast mutants for sensitivity to the IMP dehydrogenase inhibitor
6-azauracil. Yeast 21:241–248.
33. Schaft, D., A. Roguev, K. M. Kotovic, A. Shevchenko, M. Sarov, A.
Shevchenko, K. M. Neugebauer, and A. F. Stewart. 2003. The histone 3 lysine
36 methyltransferase, SET2, is involved in transcriptional elongation. Nu-
cleic Acids Res. 31:2475–2482.
34. Schroeder, S. C., B. Schwer, S. Shuman, and D. Bentley. 2000. Dynamic
association of capping enzymes with transcribing RNA polymerase II. Genes
Dev. 14:2435–2440.
35. Shaw, R. J., J. L. Wilson, K. T. Smith, and D. Reines. 2001. Regulation of an
IMP dehydrogenase gene and its overexpression in drug-sensitive transcrip-
tion elongation mutants of yeast. J. Biol. Chem. 276:32905–32916.
36. Shilatifard, A. 2004. Transcriptional elongation control by RNA polymerase
II: a new frontier. Biochim. Biophys. Acta 1677:79–86.
37. Sims, R. J., III, R. Belotserkovskaya, and D. Reinberg. 2004. Elongation by
RNA polymerase II: the short and long of it. Genes Dev. 18:2437–2468.
38. Smith, J. S., C. B. Brachmann, I. Celic, M. A. Kenna, S. Muhammad, V. J.
Starai, J. L. Avalos, J. C. Escalante-Semerena, C. Grubmeyer, C. Wolberger,
and J. D. Boeke. 2000. A phylogenetically conserved NAD-dependent pro-
tein deacetylase activity in the Sir2 protein family. Proc. Natl. Acad. Sci.
USA 97:6658–6663.
39. Strahl, B. D., P. A. Grant, S. D. Briggs, Z. W. Sun, J. R. Bone, J. A. Caldwell,
S. Mollah, R. G. Cook, J. Shabanowitz, D. F. Hunt, and C. D. Allis. 2002.
Set2 is a nucleosomal histone H3-selective methyltransferase that mediates
transcriptional repression. Mol. Cell. Biol. 22:1298–1306.
40. Woodage, T., M. A. Basrai, A. D. Baxevanis, P. Hieter, and F. S. Collins.
1997. Characterization of the CHD family of proteins. Proc. Natl. Acad. Sci.
USA 94:11472–11477.
41. Wu, X., A. Rossettini, and S. D. Hanes. 2003. The ESS1 prolyl isomerase and
its suppressor BYE1 interact with RNA pol II to inhibit transcription elon-
gation in Saccharomyces cerevisiae. Genetics 165:1687–1702.
42. Xiao, T., H. Hall, K. O. Kizer, Y. Shibata, M. C. Hall, C. H. Borchers, and
B. D. Strahl. 2003. Phosphorylation of RNA polymerase II CTD regulates
H3 methylation in yeast. Genes Dev. 17:654–663.
43. Xiao, T., C. F. Kao, N. J. Krogan, Z. W. Sun, J. Greenblatt, M. A. Osley, and
B. D. Strahl. 2005. Histone H2B ubiquitylation is associated with elongating
RNA polymerase II. Mol. Cell. Biol. 25:637–651.
44. Zhang, W., J. R. Bone, D. G. Edmondson, B. M. Turner, and S. Y. Roth.
1998. Essential and redundant functions of histone acetylation revealed by
mutation of target lysines and loss of the Gcn5p acetyltransferase. EMBO J.
17:3155–3167.
3316 KIZER ET AL. MOL. CELL. BIOL.
